Clinical Trial Update: DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial at University College London is evaluating durvalumab in combination with the S-488210/S-488211 vaccine for non-muscle invasive bladd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• S-488210/S-488211 vaccine

Snippet

Sponsor: University College, London | Conditions: Bladder Cancer | Phase 1, Phase 2 | Status: RECRUITING